Pharmaron, Inc.

Also on record

Records under this name other than the patents Pharmaron, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 5 patents it holds.

Back to Pharmaron, Inc.

Patent	Title	Status	Expires	Confidence
US 10,329,275	Novel Compounds and Compositions for the Inhibition of Nampt conveyed to Genentech Inc. - now held by Valo Health, Inc. In force Term ends Sep 2, 2031 · High confidence	In force	Term ends Sep 2, 2031	High confidence
US 10,647,695	Novel Compounds and Compositions for the Inhibition of Nampt conveyed to Genentech Inc. - now held by Valo Health, Inc. In force Term ends Sep 2, 2031 · High confidence	In force	Term ends Sep 2, 2031	High confidence
US 11,279,687	Novel Compounds and Compositions for the Inhibition of Nampt conveyed to Genentech Inc. - now held by Valo Health, Inc. In force Term ends Sep 2, 2031 · High confidence	In force	Term ends Sep 2, 2031	High confidence
US 9,822,129	Amido Spirocyclic Amide and Sulfonamide Derivatives conveyed to Genentech Inc. - now held by Valo Health, Inc. In force Term ends Mar 1, 2033 · High confidence	In force	Term ends Mar 1, 2033	High confidence
US 10,730,889	Amido Spirocyclic Amide and Sulfonamide Derivatives conveyed to Genentech Inc. - now held by Valo Health, Inc. In force Term ends Mar 1, 2033 · High confidence	In force	Term ends Mar 1, 2033	High confidence
US 11,485,745	Amido Spirocyclic Amide and Sulfonamide Derivatives conveyed to Genentech Inc. - now held by Valo Health, Inc. In force Term ends Mar 4, 2033 · High confidence	In force	Term ends Mar 4, 2033	High confidence
US 10,179,782	Substituted Sulfonamide Compounds conveyed to Genentech Inc. - now held by F. Hoffmann-La Roche AG In force Term ends Feb 12, 2036 · High confidence	In force	Term ends Feb 12, 2036	High confidence
US 10,800,780	TDO2 Inhibitors conveyed to Genentech, Inc. In force Term ends Dec 23, 2036 · High confidence	In force	Term ends Dec 23, 2036	High confidence
US 12,583,858	TDO2 Inhibitors conveyed to Genentech, Inc. In force Term ends Dec 23, 2036 · High confidence	In force	Term ends Dec 23, 2036	High confidence
US 11,603,373	TDO2 and IDO1 Inhibitors conveyed to Genentech, Inc. In force Term ends Jun 20, 2038 · High confidence	In force	Term ends Jun 20, 2038	High confidence

10 of 25 records shown.

Pro members see all 25.

Pro members: see all 25 records